Rongchang Bio’s stock price surged as the Phase III clinical trial of Telitacicept for gMG in China was selected for an oral presentation at the 2025 AANEM.
$REMEGEN (09995.HK)$ The stock surged over 8% at the opening session. As of the time of writing, it was up […]









